SCHEMBL5776880

SCHEMBL5776880

O=C(O)Cc1cccc(S(=O)(=O)N2CCN(c3ccc(Cl)cc3)CC2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.59
THRB P10828 1/20 0.59
HDAC3 O15379 3/20 0.58
HDAC4 P56524 3/20 0.58
HDAC1 Q13547 3/20 0.58
HDAC7 Q8WUI4 3/20 0.58
HDAC2 Q92769 3/20 0.58
HDAC10 Q969S8 3/20 0.58
HDAC11 Q96DB2 3/20 0.58
HDAC8 Q9BY41 3/20 0.58
HDAC6 Q9UBN7 3/20 0.58
HDAC9 Q9UKV0 3/20 0.58
HDAC5 Q9UQL6 3/20 0.58
PTPN11 Q06124 2/20 0.52
MAPT P10636 2/20 0.50
ALDH1A1 P00352 2/20 0.50
LSS P48449 1/20 0.50
TSHR P16473 1/20 0.50
CNR1 P21554 1/20 0.49
ITGB3 P05106 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5772658 0.91 PTPN11 (0.62) LMNATHRBHDAC3HDAC4HDAC1
SCHEMBL6357532 0.90 HTT (0.58) LMNATHRBHDAC3HDAC4HDAC1
SCHEMBL5749330 0.90 THRB (0.58) LMNATHRBHDAC3HDAC4HDAC1
SCHEMBL5801275 0.89 LMNA (0.57) LMNATHRBHDAC3HDAC4HDAC1
SCHEMBL5772884 0.88 ALDH1A1 (0.57) LMNAPTPN11MAPTALDH1A1SMN1; SMN2
SCHEMBL13805030 0.86 ALDH1A1 (0.63) LMNAALDH1A1LSSSMN1; SMN2KMT2A
SCHEMBL5749090 0.85 LMNA (0.60) LMNAHDAC3HDAC4HDAC1HDAC7
SCHEMBL6348350 0.85 HSD11B1 (0.59) LMNATHRBHDAC3HDAC4HDAC1
SCHEMBL5748241 0.85 HTT (0.63) LMNAPTPN11MAPTALDH1A1TSHR
SCHEMBL5746692 0.85 TNF (0.54) LMNAHDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735280-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS Kalypsys, Inc. (US) 2006-12-27 EP disclosed
WO-2005115983-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS KALYPSYS, INC. (US) 2005-12-08 WO disclosed
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders KALYPSYS, INC. (US) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders PPARA, PPARG, PPARD LMNA 3289/4885THRB 230/4885HDAC3 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.